Close
FINDING CURES TOGETHER<sup>SM</sup>

Media Advisories

 

 

Scientists From the AACR Annual Meeting to Participate in ABC News' April 21 Twitter Chat, Breakthroughs in Cancer Research10552074/16/2015 9:07:49 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx26False2015-04-16T21:00:00Z<div class="ExternalClass1F107CDD856043D983A8AFB3902F889B"><p>The American Association for Cancer Research (AACR) President Carlos L. Arteaga, MD, PhD; President-elect José Baselga, MD, PhD; and Annual Meeting Program Chair Lewis C. Cantley, PhD, will be tweeting live during the ABC News Twitter chat Tuesday, April 21, 1-2 p.m. ET, on the latest advances in cancer research. The Twitter chat will be moderated by ABC News Medical Editor Richard Besser, MD, and will also be streamed live on <a href="https&#58;//itunes.apple.com/app/id972909677" target="_blank">Periscope</a>, an iOS app that enables users to broadcast live video.&#160; </p><p>Arteaga is president of the AACR and director of the Breast Cancer Program, director of the Vanderbilt-Ingram Cancer Center Research Network, director of the Center for Cancer Targeted Therapies at Vanderbilt-Ingram Cancer Center, and a professor of medicine and cancer biology at Vanderbilt University School of Medicine; Baselga is president-elect of the AACR and physician-in-chief and chief medical officer at Memorial Sloan Kettering Cancer Center; and Cantley is program chair of the AACR Annual Meeting 2015 and the Meyer Director of the Sandra and Edward Meyer Cancer Center, the Margaret and Herman Sokol professor in oncology research, and a professor of cancer biology medicine at Weill Cornell Medical College. </p><p>They will join a panel of other AACR members at the AACR Annual Meeting 2015, where the latest and most exciting basic, translational, and clinical discoveries in cancer research are presented to more than 18,500 attendees.&#160;&#160; </p><p>Follow the conversation on Twitter and join in&#58; <a href="https&#58;//twitter.com/search?q=%23abcDrBchat" target="_blank">#abcDrBchat</a>. </p><p>Follow the AACR on Twitter&#58; <a href="http&#58;//www.twitter.com/aacr" target="_blank">@AACR</a>.<br><a href="https&#58;//itunes.apple.com/app/id972909677" target="_blank">Download the Periscope app</a> and follow the AACR&#58; @AACR.</p></div>
Cancer Research Catalyst Blog: FDA Approves First Immunotherapy for Children With Cancer; Increasing Clinical Trial Participation9771073/26/2015 9:05:11 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx25False2015-03-26T16:00:00Z<div class="ExternalClass1CBB8CDC42B440868B083B9DD2AFA40A"><p>​<em></em><a href="http&#58;//blog.aacr.org/" target="_blank">Cancer Research Catalyst</a>, the blog of the American Association for Cancer Research (AACR), features a post from Srivani Ravoori, PhD, senior science writer at the AACR, titled <a href="http&#58;//blog.aacr.org/fda-approval-dinutuximab/" target="_blank">FDA Approves First Immunotherapy for Children With Cancer</a>.</p><p>In addition, Toni Kay Mangskau, clinical trials referral coordinator at the Mayo Clinic Cancer Center, weighs in on methods to help patients access clinical trials more easily and improve trial participation in her guest post, titled <a href="http&#58;//blog.aacr.org/a-simple-act-increasing-clinical-trial-participation/" target="_blank">A Simple Act&#58; Increasing Clinical Trial Participation</a>.</p><p>These posts are part of the continuing mission of <em>Cancer Research Catalyst</em> to further accelerate the growth and spread of knowledge about cancer, while providing helpful and interesting information to AACR members and the public. </p><p><a href="http&#58;//blog.aacr.org/" target="_blank">Visit the blog</a> and subscribe. </p></div>
American Association for Cancer Research to Participate in ABC News Twitter Chat on Colorectal Cancer9448633/17/2015 1:55:41 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx24False2015-03-17T13:00:00Z<div class="ExternalClass0BFD6E259FD141C0B5BC113A9CF50EEE"><p>The American Association for Cancer Research (AACR) will be tweeting during the ABC News Twitter chat, Tuesday, March 17, 1-2 p.m. ET, on colorectal cancer awareness and prevention. </p><p>Raymond N. DuBois, MD, PhD, past president of the AACR and executive director of the Biodesign Institute at Arizona State University, will represent the AACR on this Twitter chat. </p><p>The Twitter chat will be moderated by ABC News Medical Editor Richard Besser, MD.</p><p>Follow the conversation on Twitter and join us&#58; <a href="https&#58;//twitter.com/search?f=realtime&amp;q=%23abcDrBchat&amp;src=typd" target="_blank">#abcDrBchat </a></p><p>Follow the AACR on Twitter&#58; <a href="http&#58;//www.twitter.com/aacr" target="_blank">@AACR</a></p><p>For more information, please contact Lauren Riley at <a href="mailto&#58;lauren.riley@aacr.org">lauren.riley@aacr.org</a> or 215-446-7155 or Jeff Molter at <a href="mailto&#58;jeff.molter@aacr.org">jeff.molter@aacr.org</a> or 267-210-3965.<br></p></div>
American Association for Cancer Research to Host Annual Meeting in Philadelphia, April 18-22, 20158900273/3/2015 5:16:53 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx23False2015-03-03T05:00:00Z<div class="ExternalClass6D9616D3B4BF4A8CA2C8C0E9DA63CF6C"><p>​PHILADELPHIA – The American Association for Cancer Research (AACR) will showcase newsworthy research on clinical trials, epidemiology, immunology, epigenetics, laboratory science, and translational medicine at its <a href="/Meetings/Pages/MeetingDetail.aspx?EventItemID=25">Annual Meeting</a>, April 18-22, at the Pennsylvania Convention Center in Philadelphia.<br><br>Watch the <a href="https&#58;//www.youtube.com/watch?v=TLyVUqeMzPE&amp;feature=youtu.be&amp;list=UUxr_bGdhkdyyFo5V3qDBwGg" target="_blank">AACR Annual Meeting 2015 video. </a><br><br>The meeting will draw more than 18,500 scientists, clinicians, advocates, and others to discuss advances in the field of cancer science. Registration is complimentary for credentialed news media. Members of the media can register using <a href="/AM15-Press" target="_blank">this form</a>.<br><br>Public information officers at medical institutes and cancer centers can also register with us by contacting Lauren Riley at <a href="mailto&#58;mailto&#58;lauren.riley@aacr.org" target="_blank">lauren.riley@aacr.org</a> or 215-446-7155.<br><br>Press conferences will be held at the following times&#58;<br></p><ul><li>Sunday, April 19, 2015, 8&#58;30 a.m. ET</li><li>Monday, April 20, 2015, 8&#58;30 a.m. ET</li><li>Tuesday, April 21, 2015, 8&#58;30 a.m. ET</li></ul><p><br>The press room will be located in Room 109B (street level) of the Pennsylvania Convention Center (1101 Arch St., Philadelphia, PA 19107) and will be open from 8 a.m. to 6 p.m. ET, Saturday, April 18, to Tuesday, April 21, and from 8 a.m. to noon ET, Wednesday, April 22. The press room is a fully functioning office with computers, printers, wireless internet access, and refreshments. <br><br>Those following on social media can join the conversation on Twitter at <a href="https&#58;//twitter.com/hashtag/aacr15?f=realtime&amp;src=hash" target="_blank">#AACR15</a>.<br><br>For more information, contact&#58; Lauren Riley at <a href="mailto&#58;mailto&#58;lauren.riley@aacr.org" target="_blank">lauren.riley@aacr.org</a> or 215-446-7155, Julia Gunther at <a href="mailto&#58;julia.gunther@aacr.org" target="_blank">julia.gunther@aacr.org</a> or 267-250-5441, or Jeff Molter at <a href="mailto&#58;jeff.molter@aacr.org" target="_blank">jeff.molter@aacr.org</a> or 267-210-3965.<br></p></div>
Cancer Research Catalyst Blog: Epigenetics Research Collaboration, Newly Approved Breast Cancer Drug8313492/12/2015 7:25:28 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx22False2015-02-12T15:00:00Z<div class="ExternalClass37A12B63F6504D389359DDDE59F3E7A8"><p><em></em><a href="http&#58;//blog.aacr.org/" target="_blank"><em>Cancer Research Catalyst</em></a>, the blog of the American Association for Cancer Research (AACR), features a guest post from Peter A. Jones, PhD, DSc, research director and chief scientific officer at the Van Andel Research Institute, titled <a href="http&#58;//blog.aacr.org/vari-su2c-epigenetics-dream-team/" target="_blank">Harnessing Epigenetics and Collaboration to Positively Impact Patients</a>.</p><p>In addition, Karen Honey, PhD, senior managing editor of science communications at the AACR, discusses the latest U.S. Food and Drug Administration cancer drug approval—palbociclib (Ibrance)—in her post, <a href="http&#58;//blog.aacr.org/fda-approval-palbociclib/" target="_blank">Ongoing Progress Against Cancer&#58; New Breast Cancer Therapeutic Approved</a>. </p><p>These posts are part of the continuing mission of <em>Cancer Research Catalyst</em> to further accelerate the growth and spread of knowledge about cancer, while providing helpful and interesting information to AACR members and the public. </p><p><a href="http&#58;//blog.aacr.org/" target="_blank">Visit the blog</a> and subscribe. </p></div>
Cancer Research Catalyst Blog: A Look Ahead to 20157692591/27/2015 4:48:47 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx21False2015-01-27T17:00:00Z<div class="ExternalClass17A32793D33E40B9AFBA0AFBDF606C86"><p>​<em></em><a href="http&#58;//blog.aacr.org/" target="_blank">Cancer Research Catalyst</a>, the blog of the American Association for Cancer Research (AACR), features a new post, <a href="http&#58;//blog.aacr.org/experts-forecast-cancer-prevention-therapies-2015/" target="_blank">Experts Forecast Cancer Prevention and Therapies in 2015</a>, which discusses potential breakthroughs in cancer research expected in the upcoming year.</p><p>Srivani Ravoori, PhD, AACR senior science writer, interviewed three eminent AACR experts on promising cancer research areas—immunotherapy, cancer genomics, and cancer prevention—for this post.</p><p>These posts are part of the continuing mission of Cancer <em>Research Catalyst</em> to further accelerate the growth and spread of knowledge about cancer, while providing helpful and interesting information to AACR members and the public. </p><p>Visit the blog at <a href="http&#58;//blog.aacr.org/" target="_blank">http&#58;//blog.aacr.org</a> and subscribe. </p></div>
​Cancer Research Catalyst Blog Discusses Personalized Oncology and Cell Biology7240101/16/2015 4:41:46 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx20False2015-01-16T14:30:00Z<div class="ExternalClassB21EB1A296F044FBB67B18361B73715F"><p><em></em><a href="http&#58;//blog.aacr.org/" target="_blank">Cancer Research Catalyst</a>, the blog of the American Association for Cancer Research (AACR), features a guest post, “<a href="http&#58;//blog.aacr.org/plugging-cell-biology-genomic-world/" target="_blank">Plugging Cell Biology Into a Genomic World</a>,” about the integration of cell biology with genomics to enhance personalization of cancer treatment, from AACR member and cancer cell biologist Adam Marcus, PhD.</p><p>Marcus is also an associate professor at Emory University School of Medicine in Atlanta and director of a research laboratory at Winship Cancer Institute of Emory University focusing on cell biology and pharmacology in lung and breast cancers.</p><p>The post also includes Marcus’ recent TEDxPeachtree talk, “Every Cancer is Personal.”</p><p>These posts are part of the continuing mission of Cancer Research Catalyst to further accelerate the growth and spread of knowledge about cancer, while providing helpful and interesting information to AACR members and the public.</p><p><a href="http&#58;//blog.aacr.org/" target="_blank">Visit the blog</a> and subscribe. </p></div>
Cancer Research Catalyst Previews Ken Burns-produced PBS Documentary on Cancer6972271/9/2015 3:19:18 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx19False2015-01-09T14:00:00ZThree-part series slated to air March 30-April 1<div class="ExternalClass55BB0F748C114B209332BAB25F0F80FC"><p><em><a href="http&#58;//blog.aacr.org/" target="_blank">Cancer Research Catalyst</a></em>, the blog of the American Association for Cancer Research (AACR), features a <a href="http&#58;//blog.aacr.org/cancer-emperor-of-all-maladies-documentary/" target="_blank">post</a> on the making of the PBS documentary, <em>Cancer&#58; The Emperor of All Maladies</em> (the AACR is a supporter). Noted documentary filmmaker Ken Burns is the executive producer, co-writer, and senior creative consultant for the project, which is based on Siddhartha Mukherjee’s Pulitzer Prize-winning book, <em>The Emperor of All Maladies&#58; A Biography of Cancer</em>.</p><p>For <a href="http&#58;//blog.aacr.org/cancer-emperor-of-all-maladies-documentary/" target="_blank">this post</a>, Kevin McLaughlin, executive editor of the AACR’s <em><a href="http&#58;//www.cancertodaymag.org/Pages/default.aspx" target="_blank">Cancer Today</a></em>, discusses the making of this documentary. </p><p>These posts are part of the continuing mission of <em>Cancer Research Catalyst</em> to further accelerate the growth and spread of knowledge about cancer, while providing helpful and interesting information to AACR members and the public. </p><p><a href="http&#58;//blog.aacr.org/" target="_blank">Visit the blog</a> and subscribe. </p></div>
Molecular Targets and Cancer Therapeutics 26th EORTC-NCI-AACR Symposium49753811/13/2014 3:42:41 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx18False2014-11-13T14:00:00ZNov. 18-21, 2014; Barcelona, Spain<div class="ExternalClassE53098A8E36C4E229A63AD34F69BB3CE"><p>​<strong><em>Editor’s Note</em></strong><em>&#58; In a </em><a href="http&#58;//blog.aacr.org/qa-lee-helman-md-cancer-targets-therapeutics/" target="_blank"><em>post published today</em></a><em> on the AACR blog, </em><a href="http&#58;//blog.aacr.org/" target="_blank">Cancer Research Catalyst</a><em>, the National Cancer Institute’s Lee Helman, MD, co-chair of the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, discusses what to expect this year, and peers into the future of targeted cancer therapies and immunotherapy.</em></p><p>Journalists are invited to attend this meeting held by the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI), and the American Association for Cancer Research (AACR). <a href="http&#58;//www.ecco-org.eu/Events/EORTC_NCI_AACR_2014/Media" target="_blank">Registration</a> is free for credentialed journalists. </p><p>The <a href="/Meetings/Pages/MeetingDetail.aspx?EventItemID=18">EORTC-NCI-AACR Symposium</a> is the premier scientific forum for researchers developing the cancer drugs of the future. Understanding the pathways and mechanisms that cause cancer and regulate the biological behavior of tumor cells has led to the development of numerous new agents, &quot;designer&quot; diagnostics, prognostic tests, &quot;smart&quot; drugs, innovative targets for clinical trials, and other new ways of tackling cancer. Around 2,200 international cancer experts will be attending the meeting to discuss the latest breakthroughs in preclinical and clinical research to facilitate further advances against cancer.</p><p>The majority of the abstracts are <a href="http&#58;//www.ecco-org.eu/ENA" target="_blank">available online</a>. Some, including late-breaking abstracts and those that form part of the official media program, will only be embargoed and published online on the day of presentation.</p><p>Examples of highlighted research include&#58; </p><ul><li>First report from a phase I clinical trial of a first-in-class drug, AG-120, in patients with advanced hematologic malignancies with the IDH1 mutation; </li><li>Updated interim results from the ongoing phase II clinical trial examining the potential of rociletinib, a new drug that targets mutant EGFR, including theT790M mutant, as a treatment for non-small cell lung cancer;</li><li>Early results of the safety and efficacy of ASP 8273, an inhibitor of mutant EGFR, including the T790M mutant;</li><li>Report on the safety and efficacy of a combination therapy (the BRAF V600 inhibitor encorafenib, the EGFR-targeted monoclonal antibody cetuximab, with or without the P13K inhibitor alpelisib) to treat patients with advanced colorectal cancer with the BRAF mutation; </li><li>Interim results from a phase II clinical trial testing a combination of bevacizumab and erlotinib as a treatment for metastatic papillary kidney cancer;</li><li> Preclinical science and updated results from ARMOR2, a phase II clinical trial testing galeterone in men with castration-resistant prostate cancer; and</li><li>Results from a phase I clinical trial pioneering a new approach to treating HPV-related cervical cancer.</li></ul><p>Sessions are open to journalists and registration information is <a href="http&#58;//www.ecco-org.eu/Events/EORTC_NCI_AACR_2014/Media" target="_blank">available online</a>.</p><p>A media center with international phone and internet connections will be available.</p><p>The official language of the symposium is English and all press materials will be in English.</p><p><strong>For media queries about the symposium, contact&#58; </strong></p><p>Emma Mason, media consultant<br><a href="mailto&#58;wordmason@mac.com">wordmason@mac.com</a> <br>+44 (0) 7711 296 986</p><p>Jeremy Moore, American Association for Cancer Research<br><a href="mailto&#58;jeremy.moore@aacr.org">jeremy.moore@aacr.org</a><br>267-250-5441</p><p><strong>Accommodations</strong></p><p>Get information on <a href="http&#58;//www.ecco-org.eu/Events/EORTC_NCI_AACR_2014/Travel-and-Accommodation" target="_blank">accommodations in Barcelona</a>.</p><p><a href="https&#58;//twitter.com/search?f=realtime&amp;q=%23ENA2014" target="_blank"><img class="ms-rte-paste-setimagesize" alt="Twitter" src="/PublishingImages/Twitter-bird-blue-on-white_50x50.jpg" style="margin&#58;5px;" /></a><a href="https&#58;//twitter.com/search?f=realtime&amp;q=%23ENA2014" target="_blank">#ENA2014</a></p></div>
2014 San Antonio Breast Cancer Symposium to Be Held Dec. 9-1345961311/3/2014 4:46:34 PMhttp://www.aacr.org/Newsroom/Lists/Media Advisories/AllItems.aspx17False2014-11-03T14:00:00Z<div class="ExternalClass660DF9BD924342BB8B29D00A4573325F"><p>SAN ANTONIO — The American Association for Cancer Research, The Cancer Therapy &amp; Research Center at The University of Texas Health Sciences Center at San Antonio, and Baylor College of Medicine will be hosting the <a href="http&#58;//www.sabcs.org/" target="_blank">2014 San Antonio Breast Cancer Symposium</a>, Dec. 9–13, at the Henry B. Gonzalez Convention Center, San Antonio.</p><p>The symposium provides news on state-of-the-art breast cancer research, including experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease. </p><p><a href="http&#58;//www.sabcs.org/ProgramSchedule/index.asp" target="_blank">View</a> the scientific program.</p><p>Please note the 2014<strong> embargo policy</strong>&#58; All data at the 2014 San Antonio Breast Cancer Symposium lifts embargo at 8 a.m. CT, Dec. 9, with the exception of research being presented in the official press program, which is designated to lift at date and time of presentation during an official press conference.</p><p>Official press conferences will take place 7&#58;30 a.m. CT, Wednesday, Dec. 10; Thursday, Dec. 11; and Friday, Dec. 12.<br>A press kit containing releases and highlighted abstracts will be available in early December. </p><p>Registration will be available to members of the media who provide credentials. For more information or to register for the meeting, please contact Lauren Riley at <a href="mailto&#58;lauren.riley@aacr.org">lauren.riley@aacr.org</a> or 215-446-7155 or Jeremy Moore at <a href="mailto&#58;jeremy.moore@aacr.org">jeremy.moore@aacr.org</a> or 215-446-7109.</p><p><a href="https&#58;//twitter.com/search?f=realtime&amp;q=%23SABCS14" target="_blank"><img alt="Twitter bird" src="/PublishingImages/Twitter-bird-blue-on-white_50x50.jpg" style="margin&#58;5px;" /></a><a href="https&#58;//twitter.com/search?f=realtime&amp;q=%23SABCS14" target="_blank">#SABCS14</a></p></div>